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a b s t r a c t
Using immortalized hypothalamic GT1-7 neurons, which express the CB1 cannabinoid receptor (CB1R)
and three Ca2+ channel types (T, R and L), we found that the CB1R agonist WIN 55,212-2 inhibited the
voltage-gatedCa2+ currentsbyabout35%. The inhibitionbyWIN55,212-2 (10M)was reversible andpre-
vented by nifedipine (3M), suggesting a selective action on L-type Ca2+ channels (LTCCs). WIN 55,212-2
action exhibited all the features of voltage-independent Ca2+ channel modulation: (1) no changes of the
activation kinetics, (2) equal depressive action at all potentials and (3) no facilitation following strong
prepulses. At variancewithWIN55,212-2, the CB1R inverse agonist AM-251 (10M) caused 20% increase
of Ca2+ currents. The inhibition of LTCCs by WIN 55,212-2 was prevented by overnight PTX-incubation
and by intracellular perfusion with GDP--S. The latter caused also a 20% Ca2+ current up-regulation.
WIN 55,212-2 action was also prevented by application of the PKA-blocker H89 or by loading the neu-
ronswith 8-CPT-cAMP. Our results suggest that LTCCs in GT1-7 neurons are partially inhibited at rest due
to a constitutive CB1R activity removed by AM-251 and GDP--S. Activation of CB1R via PTX-sensitive
G proteins and cAMP/PKA pathway selectively depresses LTCCs that critically control the synchronized
spontaneous firing and pulsatile release of gonadotropin-releasing hormone in GT1-7 neurons.
© 2009 Elsevier Ltd. All rights reserved.
1. Introduction
Cannabinoids are the primary psychoactive constituents of
marijuana that have profound effects on pain perception, neural
convulsions, memory and motor coordination [1,2]. Their effects
are most commonly mediated by the CB1 cannabinoid receptor
(CB1R), which is highly expressed in a variety of brain regions,
including the hypothalamus [3–5]. The CB1R is a member of the
G protein-coupled receptor superfamily [6] which acts by inhibit-
ing adenylate cyclase (AC) activity [7], delaying the opening of
voltage-gatedN- and P/Q-type channels [8–11], activating K+ chan-
nels [12,13] and triggering MAP kinases signal cascades [14]. All
these effects are originated from the activation of PTX-sensitiveGi,o
proteins coupled to CB1Rs, which inhibit AC activity and reduces
cytoplasmic cAMP levels. Inhibition of AC and reduction of cAMP is
a common pathway to most CB1R-mediated effects, but curiously
enough, this pathway does not apply to the cannabinoid-induced
modulation of voltage-gated K+ and Ca2+ channels, which is medi-
∗ Corresponding author. Tel.: +39 011 670 8489; fax: +39 011 670 8174.
E-mail address: emilio.carbone@unito.it (E. Carbone).
1 These two authors contributed equally to the work.
ated by Gi,o proteins acting directly on the channels, regardless of
cAMP or any other diffusible messenger [15]. The only exception to
this rule is the activation of the fast inactivating IA potassium cur-
rent inducedby theCB1R/CB2RagonistWIN55,212-2 indissociated
hippocampal neurons through a PTX- and cAMP/PKA-dependent
pathway [16].
Cannabinoids act also on L-type Ca2+ channels (LTCCs) but,
despite much work, the results remain controversial. CB1R acti-
vation could not affect [9,17], up-regulate [18,19] or inhibit LTCCs
[20]. In arterial smooth muscles and in NTS (nucleus of tractus soli-
tarius) neurons, activation of CB1R causes a voltage-independent
inhibition of LTCCs which is prevented by PTX [21,22]. The inhib-
ited currentdisplays the sameactivation timecourseof controls (no
delay of the rising phase) and thedegree of inhibition remains unal-
tered after strong facilitatory prepulses, which are typical features
of the LTCCs down-modulation in response to receptor-activated
Gi,o proteins [23] (see [24] for a review). In addition, the inhibition
of LTCCs by cannabinoids in NTS is mediated by cAMP and PKA.
BlockingPKAorACactivity the inhibitoryactionofWIN55,212-2on
LTCCs is prevented [22]. This is consistent with the effects of other
Gprotein-coupled receptor-mediated signaling onneuroendocrine
LTCCs that are regulated by cAMP/PKA [25] and highlights the
markedly different mechanism by which CB1R activation inhibits
0143-4160/$ – see front matter © 2009 Elsevier Ltd. All rights reserved.
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L- and non-L-type channels. Despite being PTX-sensitive, the latter
action on non-L-type channels (N and P/Q) is voltage-dependent
and insensitive to cAMP [15].
Given the key role that LTCCs play in the control of many
brain functions and the little knowledge on CB1R-mediated signal
transduction mechanisms targeting these channels, we thought of
interest to study the action of CB1R on LTCCs expressed in hypotha-
lamic immortalized GT1-7 neurons. GT1-7 clonal cells produce and
release the gonadotropin-releasing hormone (GnRH) [26]. They
also express CB1Rs and are able to synthesize and release endo-
cannabinoids [27]. GT1-7 neurons form stable networks that fire
spontaneously and possess high densities of LTCCs. These channels
play an important role in the control of synchronized firings and
consequent pulsatile GnRH release [28,29]. In addition, cAMP sig-
naling and a variety of G protein-coupled receptors regulate GnRH
release in GT1-7 neurons [30]. Thus, immortalized GnRH neurons
appear to be an ideal model for studying the CB1R-mediated mod-
ulation of neuronal LTCCs.
We report here that the CB1R agonist WIN 55,212-2 selectively
inhibits LTCCs in immortalizedGT1-7 neurons. This selective action
ismediated by PTX-sensitive Gi,o proteins through a cAMP/PKA sig-
nal transduction pathway. Inhibition is voltage-independent and
insensitive to short facilitatory prepulses excluding a direct Gi,o-
mediated action on the non-L-type channels expressed in GT1-7
cells (R-type; [31]). This newmodulatory action onneuroendocrine
LTCCs could be critical in the control of GnRH release in hypotha-
lamic neurons and broadens the possible mechanisms by which
cannabinoids could affect cell excitability, neuronal firing andCa2+-
dependent hormone release.
2. Material and methods
2.1. Tissue culture of immortalized GT1-7 neurons
ImmortalizedGT1-7neurons (providedbyDr. P.Mellon,Univer-
sity of California, San Diego, La Jolla, USA) were cultured in 4.5 g/l
glucose Dulbecco’s modified Eagle’s medium (DMEM) supple-
mentedwith 10% fetal bovine serum, 2% of l-glutamine, 100U/ml
penicillin and 100g/ml streptomycin in an atmosphere of 5% CO2
at 37 ◦C. Morphological differentiation was optimized by culturing
the cells just after they reached confluence in a medium containing
B27 serum-free supplement, 1% sodium pyruvate, 0.5% fetal bovine
serum and 2% of l-glutamine. The culture medium was changed
every 3–4 days, and cells used in this study were between passages
9 and 14.
2.2. Electrophysiology
The Ca2+ currents were recorded by using two configurations:
theperforated-patchwithamphotericinBand thewhole-cell. Patch
electrodes were made of borosilicate glass capillaries and had a
resistance of 1–2M. For the perforated patch-clamp configura-
tion [25], the pipette solution contained (in mM): 135 CsMeSO3,
8 NaCl, 2 MgCl2, 20 HEPES and 50–100g/ml of amphotericin B
(pH 7.3 with CsOH); for the whole-cell configuration the solution
contained (mM): 95 CsCl, 30 TEACl, 10 EGTA, 2 MgCl2, 10 HEPES,
8 glucose, 2 ATP, 0.5 GTP, 15 phosphocreatine (pH 7.3 with CsOH).
The extracellular solution contained (in mM): 135 TEACl, 10 CaCl2,
2 MgCl2, 10 HEPES, 10 glucose (pH 7.4 with CsOH).
Electrophysiological recordings were performed either using an
EPC-9patch-clampamplifier andPULSE software (HEKAElectronic,
Lambrecht, Germany) [25] or using an Axopatch 200-A amplifier
and pClamp 10.0 software programs (Axon Instruments Inc., Foster
City, CA, USA) [32]. Currents were sampled at 10kHz and filtered
at 1–5kHz. Recordings were made at room temperature.
2.3. RNA extraction and PCR-RT for CB1R and CB2R in GT1-7
neurons
Total RNA from GT1-7 cells was isolated with Mini RNeasy
(Qiagen AG, Basel, Switzerland) as indicated in the manufac-
turer’s instructions. DNase-treated total RNA was used in the
reversed transcription (RT) procedure. cDNA was synthesized in
a total volume of 50l with the High Capacity cDNA Archive
kit (Applied Biosystems, Foster City, CA, USA) according to the
manufacturer’s protocol. The primer sequences used were as
follows: for CB1R (U22948), 5′-TGTGGGGAGAATTTTATGGA (for-
ward) and 5′-AGATTGCAGCTTCTTGCAGT (reverse); for CB2R (NM
009924), 5′-GGTCCTCTCAGCATTGATTTCTTAC (forward) and 5′-
TTCACATCAGCCTCTGTTTCTGTA (reverse); forGAPDH (M32599) 5′-
CAACAGCAACTCCACTCTT (forward); 5′-AGGCCCCTCCTGTTATTATG
(reverse). Polymerase chain reaction (PCR) was carried out in a
total volume of 25l containing 2l of cDNA from the above reac-
tion, 0.5Mof each specificprimer, 0.5UPhusionDNApolymerase,
5× Phusion GC buffer, 0.2% DMSO (FinnzymesOy, Espoo, Finland),
0.2mM of each deoxynucleotide triphosphate (Invitrogen, Carls-
bad, CA, USA). The reaction conditions were 98 ◦C for 30 s, followed
by 30 cycles (for CB1R and GAPDH) or 35 cycles (for CB2R) at 98 ◦C
for 15 s, 58 ◦C for 30 s, and 72 ◦C for 30 s. Positive controls (cDNA
obtained from total mouse brain total RNA) and negative controls
(water instead of template) were amplified in the same condition
and glyceraldehyde-3-phosphate dehydrogenasewas used to eval-
uate the integrity ofRNA. Theamplifiedproductswere separatedon
2% agarose gels with Gel star (Cambrex Corporation, East Ruther-
ford, NJ, USA) and in the presence of a 100bp DNA ladder as the
molecular weight marker (Promega; Madison, WI, USA).
2.4. Chemicals
WIN 55,212-2, AM-251 and GDP--S were purchased from
Tocris Bioscience (Avonmouth, UK). Nifedipine, 8-CPT-cAMP, and
H89 were purchased from Sigma–Aldrich (Milano, Italy). All drugs
wereprepared just before use.WIN55,212-2 andAM-251weredis-
solved in dimethyl sulfoxide (DMSO) in stocks of 10mM and both
used at the final concentration of 1–10M. GDP--S was dissolved
in water in stocks of 50mM and used at the final concentration
of 170–500M. Nifedipine was dissolved in ethanol and prepared
to the final concentration of 3M. PTX was purchased from Cal-
biochemCorporation (Darmstadt, Germany) anddissolved inwater
in stocks of 50g/ml. GT1-7 neurons were incubated overnight
with 130ng/ml of toxin. 8-CPT-cAMP and H89 were dissolved in
water in stocks of 10mM and 1mM and used at the final concen-
tration of 1mM and 5M, respectively.
2.5. Statistical analysis
The results are expressed as the mean± S.E.M. for n number of
neurons. The differences were analyzed by either one-sample or
paired Student’s t-tests as indicated. Values of p<0.05 were con-
sidered statistically significant.
3. Results
3.1. Expression of CB1R and CB2R in GT1-7 neurons
The presence of cannabinoid receptors (CB1R and CB2R) in
GT1-7 neurons was supported by qualitative RT-PCR experiments
performed on the total RNA extracted from GT1-7 cells and
mouse brain RNA (positive control). Total RNA extracted was
retro-transcribed and amplified with specific oligonucleotides for
CB1R and CB2R. To evaluate RNA integrity we used primers for
GAPDH (glyceraldehyde-3-phoshate dehydrogenase) specifically
Author's personal copy
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Fig. 1. RT-PCR demonstrates the presence of CB1R and CB2R mRNA in GT1-7 neu-
rons. (A) RT-PCR analyses of CB1R expression in GT1-7 cells (lane 1). Lanes 1 and 2
show samples from GT1-7 cells, lanes 4 and 5 are from mouse brain (positive con-
trol). The enzyme GAPDH (lanes 2 and 5) was used as housekeeping gene. Products
were separated via electrophoresis on 2% agarose gel containing ethidium bromide
in the presence of specific molecular weights (MW) (lane 3). (B) RT-PCR analyses
of CB2R expression in GT1-7 cells (lane 1). Lanes 1 and 2 show template from GT1-
7; lanes 4 and 5 show samples from mouse brain (positive control). Lane 3 is the
molecular weights marker.
expressed in GT1-7 cells and mouse brain. Qualitative RT-PCR
shows the presence of both cannabinoid receptors in GT1-7 neu-
rons: CB1R mRNA (lane 1, Fig. 1A) and CB2R mRNA (lane 1, Fig. 1B).
As positive control, expression of CB1R and CB2R was evaluated in
the mouse brain (lane 4, Fig. 1A and B) and GAPDH was used as
housekeeping gene (lanes 2 and 5; Fig. 1A and B).
3.2. LVA and HVA Ca2+ currents in GT1-7 neurons
GT1-7 neurons express low-voltage activated (LVA, T-type) and
high-voltage activated (HVA) Ca2+ channels [33]. The HVA com-
ponent is further subdivided in two channel types (L and R) with
percentages of expression varying from cell to cell [31,28]. We
found on average that 30% of GT1-7 neurons expressed fast inac-
tivating T-type channels that activated from −50mV in 10mM
Ca2+ (holding potential, Vh, −80mV) and reached maximal ampli-
tudes at −10mV (Fig. 2A and B). Slowly inactivating HVA channels
were found to activate above −40mV (Fig. 2C) and reached maxi-
mal amplitudes at +10mV (Fig. 2D). HVA Ca2+ currents had mean
amplitudes of 196.6±16.6pA at +10mV (n=81) that normalized
for the cell capacitance (33.2±3.2pF; n=81) gave mean current
densities of 5.9±0.8pA/pF. TheT-type channelshad the typical gat-
ing characteristics described in these [28] and other neurons [34].
They activated below −40mV, had voltage-dependent activation
and fast inactivation and were inactivated at Vh around −50mV.
Their presence caused rapid inactivating currentsduring stepdepo-
larization and an early current peak around −10mV during ramp
commands (Fig. 2B). In this work the T-type channels were not
further considered.
To simplify our analysis, we tested the percentage of LTCCs
expressed by GT1-7 neurons by determining the blocking effects
of 3M nifedipine. We found that the DHP-antagonist on average
blocked 49.4±3.0% (n=12) of the total HVA currents activated at
+10mV from Vh =−80mV (Fig. 3A and C). DHP block was fast and
reversible and, could be complete in 30% of the cells, indicating the
presence of only LTCCs in a fraction of GT1-7 neurons (Fig. 3B). The
residualDHP-resistant currents (∼50%of the total)werenot further
pharmacologically dissected and, from here on, will be indicated as
the non-L-type current component (Fig. 3C). In previous studies
the HVA Ca2+ currents of GT1-7 neurons were identified mainly as
LTCCs (100% of the total) [28] or carried mostly by R-type chan-
Fig. 2. Ca2+ currents in GT1-7 neurons expressing different percentages of LVA (T-type) and HVA (L- and non-L-type) channels. (A) Overlapped Ca2+ current traces recorded in
10mM Ca2+ from a GT1-7 neuron expressing high densities of T-type channels. Step depolarizations were from −50 to +10mV. The holding potential (Vh) was −80mV. (B) I–V
characteristics recorded from a GT1-7 neuron expressing T-type and HVA Ca2+ channels using a ramp command from −60 to +60mV (Vh −80mV). Notice the typical double-
peak indicative of the presence of LVA and HVA channels. (C and D) Overlapped Ca2+ current traces and I–V characteristics recorded from two GT1-7 neurons expressing
mostly HVA channels. Sequential step depolarizations in (C) were from −50 to −10mV (Vh −80mV); traces at more positive potentials are not shown to avoid confusing
overlapping. The ramp command was as in (B). Notice the absence of the “early shoulder” associated to T-type currents.
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Fig. 3. GT1-7 neurons express different densities of LTCCs. (A and B) Two examples of Ca2+ current block recorded at +10mV (Vh −80mV) from neurons with different
sensitivity to nifedipine (3M). In (A) the DHP blocked nearly 50% of the control current (red trace) while in (B) the DHP blocked completely the total current. In both cases
the DHP action was fully reversible (blue trace). (C) Mean percentage of current amplitude in the presence of 3M nifedipine from GT1-7 neurons responding partially to the
DHP (n=12). The percentage of current is expressed relative to the peak control current (**p<0.01 vs. control using a one-sample analysis Student’s t-test when comparing
the mean percentage values to hundred).
nels (75% of the total) [31]. Our data are in fair agreement with
both reports indicating significant degree of heterogeneity of Ca2+
channels expression in GT1-7 neurons, which might derive from
different tissue culture conditions.
3.3. Ca2+ currents inhibition by WIN 55,212-2 is
voltage-independent
GT1-7 cells express CB1R (Fig. 1) and recent works have shown
that their activation by WIN 55,212-2 reduces the release of GnRH
from these cells [27]. A likely mechanism is that WIN 55,212-2
might block the LTCCs that control both, the rate of synchronized
action potential firing and pulsatile GnRH release [29]. We tested
therefore the effects ofWIN55,212-2 on theCa2+ currents activated
at +10mV using saturating concentrations (1–10M) and looked
for its effects on the amplitude and kinetics of Ca2+ currents. Direct
application of WIN 55,212-2 on GT1-7 neurons produced an aver-
age Ca2+ current inhibition of 34.4±1.6% (n=13; p<0.01 respect to
normalized control) (Fig. 4A–C). The inhibition was fast, reversible
and required less than 1min to reach maximal values (Fig. 4D).
Recovery had similar kinetics to the onset of inhibition.
Ca2+ current inhibition by WIN 55,212-2 was of the same per-
centage at every potential and had no marked effects on the
time course and voltage-dependence of channel activation. The
half-time to peak at +10mV was 0.76±0.17ms in control and
0.75±0.15ms with WIN 55,212-2 (n=8). In addition, the I–V curve
from −60 to +60mV in the presence of the CB1R agonist had the
sameshapeof thecontrol I–Vandwas simply scaled-downbyacon-
stant factor (Fig. 4B). This is a clear indication that WIN 55,212-2
action is voltage-independent and thus different from the voltage-
Fig. 4. Inhibition the Ca2+ currents by WIN 55,212-2 in GT1-7 neurons is voltage-independent. (A) Current traces recorded at +10mV from a GT1-7 neuron before (control,
black trace), during (WIN, red trace) and after (wash, blue trace) exposure of 10M WIN 55,212-2. (B) I–V characteristics in control conditions and during application of
10M WIN 55,212-2. Notice the proportional decrease of the current with WIN 55,212-2 at every potential. (C) Mean percentage of current amplitude in the presence of
10M WIN 55,212-2 obtained from n=13 neurons. The percentage of current is expressed relative to the peak control current (**p<0.01 vs. control using a one-sample
analysis Student’s t-test when comparing themean percentage values to hundred). (D) Time course of peak Ca2+ currents at +10mV before, during and after addition of 10M
WIN 55,212-2. In the inset are shown the current traces recorded at the time indicated by the letters (a–c). (E) Ca2+ currents at control (black trace) and during exposure of
10M WIN 55,212-2 (red trace) recorded using the double-pulse protocol illustrated on the top. The prepulse depolarization to +80mV was not able to relieve the inhibition
of the Ca2+ current induced by WIN 55,212-2.
Author's personal copy
H. Hoddah et al. / Cell Calcium 46 (2009) 303–312 307
Fig. 5. The Ca2+ current inhibition induced by WIN 55,212-2 is selective for LTCCs. (A and B) Current traces recorded at +10mV and I–V characteristics at control (black
trace), in the presence of 3M nifedipine (red trace) and during application of nifedipine plus 10M WIN 55,212-2 (blue trace) from a GT1-7 neuron. (C) Mean peak current
amplitudes recorded at +10mV in the presence of nifedipine and nifedipine plus WIN 55,212-2 (n=11). The relative peak current values are normalized with respect to
control (**p<0.01 vs. control using a one-sample analysis Student’s t-test when comparing the mean percentage values to hundred).
dependent inhibition induced by cannabinoids in cell preparations
expressing N and P/Q-type channels [9]. Ca2+ current inhibition by
WIN55,212 in these casesproducedanetdelayofCa2+ channel acti-
vation at voltages below +10mV that was largely relieved at more
positive potentials (>+40mV). Strong prepulses of 50ms to +80mV
anticipating the test pulse could relief most of the inhibition [10].
In the case of GT1-7 neurons the same strong prepulses to +80mV
(n=11) was unable to remove the inhibition induced by WIN
55,212-2. PercentageofCa2+ currentdepressionwithWIN55,212-2
(34%) was identical before and after the prepulse (Fig. 4E), indicat-
ing that WIN 55,212-2 action was voltage-independent. There was
neither an acceleration of Ca2+ current activation nor an increase
of peak amplitude after the prepulse which could suggest a facil-
itatory effect of voltage as for N- and P/Q-type channels (see [35]
for a review).
3.4. WIN 55,212-2 and the CB1R inverse agonist AM-251 act
selectively on LTCCs
The inhibitory effects of WIN 55,212-2 are selective for LTCCs
and prevented by nifedipine. In the presence of the DHP (3M),
WIN 55,212-2 had no further inhibitory effects during step depo-
larization to +10mV (Fig. 5A) or during ramp commands (Fig. 5B).
Thiswas systematically observed in elevenGT1-7 neurons inwhich
the relative peak amplitude of the current with nifedipine was
52.7±4.9% with respect to control and decreased to 47.4±4.8%
after addition of WIN 55,212-2 (Fig. 5C).
Further support to a specific effect of CB1Rs activation on LTCCs
in GT1-7 neurons comes from the observation that the selective
CB1R inverse agonist AM-251 produced an effect opposite to WIN
55,212-2. AM-251 (10M) caused a net up-regulation of Ca2+ cur-
Fig. 6. The CB1R inverse agonist AM-251 up-regulates LTCCs in GT1-7 neurons. (A and B) Current traces recorded at +10mV and I–V characteristics at control (black trace)
and during application of 10M AM-251 (red trace) in two different GT1-7 neurons. Notice in (B) the selective increase of the second peak associated to the HVA currents.
(C) Time course of peak Ca2+ currents at +10mV before, during and after addition of 10M AM-251. In the inset are shown the current traces recorded at the time indicated
by the letters (a–c). (D) Mean percentage of current amplitude in the presence of 10M AM-251 from n=8 GT1-7 neurons. The percentage is expressed relative to the peak
control current (**p<0.01 vs. control using a one-sample analysis Student’s t-test when comparing the mean percentage values to hundred). (E) Current traces recorded at
+10mV in the presence of 3M nifedipine (black trace) and during application of nifedipine plus 10M AM-251 (red trace) from a GT1-7 neuron. (F) Mean peak current
amplitudes recorded at +10mV in the presence of nifedipine and nifedipine plus AM-251 (n=8). The relative peak current values are normalized with respect to control
(**p<0.01 vs. control calculated as in (D).
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rents at +10mV (Fig. 6A). The up-regulation was selective for the
HVA Ca2+ channels (Fig. 5B), required 1–2min to reach maximal
values (Fig. 5C), and was systematically observed in every GT1-
7 neuron tested (n=8). The percentage of up-regulation relative
to control varied from 6 to 44% with a mean value of 19.7±4.9%
(p<0.01 vs. normalized control; Fig. 6D) and was fully prevented
by 3M nifedipine (Fig. 6E). Simultaneous application of AM-251
and nifedipine caused no further decrease of the peak current than
the DHP alone (Fig. 6E). Mean relative amplitudes of Ca2+ currents
were 53.5±4.2% with nifedipine and 50.2±6.7% with nifedipine
plus AM-521.
3.5. WIN 55,212-2 action is prevented by PTX cell incubation and
intracellular GDP-ˇ-S
A CB1Rs hallmark is that their action on Ca2+ and K+ channels is
mediated by PTX-sensitiveGi,o proteins [15]. Overnight cell incuba-
tion with PTX is sufficient to uncouple the CB1R from Gi,o proteins
and prevents most of the effects mediated by cannabinoids [7]. The
same occurred for the CB1R-mediated effects on Ca2+ channels in
GT1-7 neurons (Fig. 7A–C).When testing the effects ofWIN55,212-
2 on a group of eight PTX-treated neurons, four of them responded
with a partial up-regulation of Ca2+ currents (mean 11.5%) and
no changes to the I–V characteristics (Fig. 7A and C), two had no
response and two responded with a partial inhibitory effect (mean
16.5%) (Fig. 7B). Taken together, these findings suggest that after
PTX treatment the inhibitory action of WIN 55,212-2 on LTCCs is
abolishedor strongly reducedandprove theexistenceof a receptor-
mediated effect of cannabinoids in GT1-7 cells.
To further confirm the involvement of a Gi,o protein in the
cannabinoid-mediated inhibition of LTCCs we tested whether also
the non-hydrolysable GDP analog, GDP--S, could prevent the
inhibitory effects of WIN 55,212-2. Fig. 7D shows an example of a
GT1-7 neuron internally perfused with 170M GDP--S. The neu-
ron initially responded to WIN 55,212-2 with a partial inhibition,
but after few minutes the inhibition was removed. In eight cells
tested, 170–500M GDP--S could remove completely the effects
of WIN 55,212-2 (Fig. 7E). We also noticed that in most GT1-7 neu-
ronsGDP--S produced a sizeable up-regulationof control currents
(10–20%), supporting the idea that a fraction of LTCCs are likely
inhibited at rest due to a basal activity of CB1R attributed to a
constitutive (agonist-independent) receptor activity.
3.6. WIN 55,212-2 effects are mediated via a cAMP/PKA pathway
Given that Gi,o proteins mediate the effect of WIN 55,212-
2, the next issue was to assay whether the G protein-mediated
inhibition was direct on LTCCs [23] or indirect through a reduc-
tion of adenylate cyclase activity with a consequent lowering of
cAMP and PKA-mediated LTCC phosphorylation [22]. For this rea-
son, we first tested whether the PKA inhibitor H89 could prevent
the WIN 55,212-2 effects. We found that either acute applica-
tion (Fig. 8A) or cell pre-incubation with 5M H89 (Fig. 8B) were
both able to prevent LTCC inhibition. In the case of Fig. 8A, WIN
Fig. 7. PTX and GDP--S prevent the inhibitory WIN 55,212-2 action on Ca2+ current in GT1-7 neurons. (A and B) Effects of 10M WIN 55,212-2 on Ca2+ currents recorded
at +10mV in two GT1-7 neurons incubated overnight with 130ng/ml PTX. In (A) the CB1R agonist caused a slight Ca2+ current increase, while in (B) caused a slight decrease.
Nifedipine (3M) was added after testing WIN 55,212-2. (C) I–V characteristics in control conditions (black trace) and during application of 10M WIN 55,212-2 (red
trace) in a GT1-7 neuron pre-incubated with PTX. (D) Effects of 10M WIN 55,212-2 on Ca2+ currents recorded at +10mV in a GT1-7 neuron intracellularly perfused with
170M GDP--S soon after having established low-resistance whole-cell recording conditions (t=1min) and 2min later (t=3min). Notice the disappearance of the WIN
55,212-2-induced inhibition and the increased current amplitude after time. (E) Percentage inhibition induced byWIN 55,212-2 in control cells (data are derived from Fig. 4C;
n=13), after PTX treatment (n=8) or during prolonged GDP--S intracellular application (n=8) (**p<0.01 vs. control using Student’s paired t-tests).
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Fig. 8. Inhibition of PKA or cell loading with 8-CPT-cAMP prevents the inhibitory effects of WIN 55,212-2 on Ca2+ currents. (A) Time course of peak Ca2+ currents at +10mV
during WIN 55,212-2 (10M), H89 (5M) and H89+WIN 55,212-2 exposure, as indicated by the horizontal bars. In the inset are shown the current traces recorded at the
time indicated by the letters (a–d). (B) Effects of WIN 55,212-2 on Ca2+ currents recorded at +10mV in a GT1-7 neuron incubated for 30min with 5M H89. After testing
WIN 55,212-2 effects, the Ca2+ current was assayed for its sensitivity to 3M nifedipine (blue trace), unmasking a nearly complete contribution of LTCCs. (C) Effects of WIN
55,212-2 on Ca2+ currents recorded at +10mV in a GT1-7 neuron incubated for 30min with 1mM 8-CPT-cAMP. (D) Percentage inhibition induced by WIN 55,212-2 in control
cells (data are derived from Fig. 4C; n=13), after chronic or acute application of H89 (n=8) or cell loading with 8-CPT-cAMP (n=4) (**p<0.01 vs. control using Student’s
paired t-tests).
55,212-2 alone caused about a 35% inhibition of the total Ca2+ cur-
rent while after applying H89 the inhibitory effect was strongly
prevented (n=5). WIN 55,212-2 had also no effects when GT1-7
neurons were incubated for 30min in a solution containing 5M
H89 (n=3). In Fig. 8B, the neuron was pre-incubated with H89
and WIN 55,212-2 had no effect on the Ca2+ current at +10mV
that was fully blocked by nifedipine. On a total of eight cells pre-
treated with H89 (acutely or chronically), WIN 55,212-2 caused a
mean inhibition of 5.1±4.5% which was significantly smaller than
the mean inhibition induced by WIN 55,212-2 alone (black bar in
Fig. 8E).
To further prove that CB1R activation proceeds via the inhi-
bition of the cAMP/PKA pathway we also tested whether loading
GT1-7 neurons with 8-CPT-cAMP could prevent the cannabinoid-
induced inhibition on LTCCs. In four cells pre-incubated for 30min
in a solution containing 1mM 8-CPT-cAMP, WIN 55,212-2 had
practically no inhibitory effects (Fig. 8C and D). This suggests that
maintaining high levels of intracellular cAMP can preserve LTCCs
functioning, regardless of any active Gi,o protein-mediated inhibi-
tion of adenylate cyclase. The results of Fig. 8 do also exclude that
CB1R-activated Gi,o proteins act directly on LTCCs, as it occurs for
the CB1R-mediated inhibition of N- and P/Q-type Ca2+ channels in
cells expressing CB1R [9,10].
4. Discussion
Weprovidedevidence that LTCCsofhypothalamic immortalized
GT1-7 neurons are selectively inhibited by the CB1 cannabinoid
receptor through Gi,o proteins and cAMP/PKA-mediated pathway.
The mechanism of LTCCs inhibition fulfills the main features of
CB1R action which involves the activation of PTX-sensitive Gi,o
proteins and the reductionof cAMP/PKAactivity [7]. There is anum-
ber of evidence supporting this conclusion. The inhibitory effect
of the cannabimimetic agonist WIN 55,212-2 is fully prevented
by nifedipine and the CB1R inverse agonist AM-251 produces an
up-regulation of LTCCs. The action of WIN 55,212-2 is abolished
by PTX cell incubation, intracellular GDP--S application, specific
PKA inhibition and by treatment with hydrolysis-resistant cAMP
analogues.
4.1. L-type versus non-L-type channel modulation by
cannabinoids
Our data clearly show that WIN 55,212-2 selectively affects
LTCCs without affecting non-L-type channels. Since GT1-7 cells
mainly express T-, L- and R-type channels [28,31], this implies
that the T- and R-type are unlikely the target of CB1R activa-
tion in these neurons. These results are in good agreement with
previous works reporting no effects on native T-type channels
in the neuroblastoma–glioma NG108-15 cell line using low con-
centrations of WIN 55,212-2 [9] but diverge from the effects on
heterologously expressed Cav3 channels which are depressed by
CB1R activation [36,37]. In this case, however, the cannabimimetic
agonists act directly on the Cav3 channel isoforms and inde-
pendently of CB1R activation. Also the lack of effects on R-type
channels is in agreement with previous works reporting no action
on somatic R-type channels in central neurons [22,38] but it is at
variance with the observation that presynaptic R-type channels
are effectively inhibited by cannabimimetic agonists at the gran-
ule cell–Purkinje neuron synapses [39]. These contrasting results
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reflect most likely the heterogeneous nature of neuronal R-type
channels [40].
At variance with the divergent findings on T- and R-type chan-
nels, there is converging evidence that CB1R activation inhibits N-
and P/Q-type channels in a voltage-dependent manner [9–11,15].
The inhibition is rapid and mediated by PTX-sensitive Gi,o proteins.
It closely resembles the one mediated by the Gi subunit and
associated to most G protein-coupled receptors [41] (see [35] for
a review). The main effect of this “membrane-delimited” modu-
lation is a delayed Ca2+ channel activation at low voltages, which
accelerates at higher potentials [42,43]. The slow activation derives
from a prolonged latency of first channel opening [44] and is fully
recovered by applying strong positive prepulses [45]. After pre-
pulse, the N- and P/Q-type currents are facilitated: they recover
their normal activation time course and increase their amplitude.
This phenomenon is commonly indicated as “voltage-dependent”
Ca2+ channel facilitation. There is, however, evidence of a direct
inhibition of P-type channels by endocannabinoids in cerebellar
Purkinje neurons that is voltage-independent and not mediated by
CB1R [46].
The CB1R-mediated inhibition of LTCCs reported here is
markedly different from that described for N- and P/Q-type
channels and in good agreement with previously reported CB1R-
mediated effects on LTCCs.WIN55,212-2 produces a 35% inhibition
of the total HVA currentwithout altering the activation time course
and strong positive prepulses do not induce any facilitation (accel-
eration of channel activation and amplitude increase). This Ca2+
channel modulation is usually indicated as “voltage-independent”
[23] (see [47] for a review). Common to the N- and P/Q-type
channels, the cannabinoids-mediated inhibition of LTCCs in GT1-
7 neurons is mediated by PTX-sensitive Gi,o proteins but differs
markedly for its sensitivity to the cAMP-dependent PKA pathway.
N- and P/Q-type channels inhibition occurs independently of dif-
fusible messengers, while LTCCs inhibition is modulated by cAMP
and PKA. Blocking PKA or preserving high levels of 8-CPT-cAMP
analogues do prevent the inhibitory effects of WIN 55,212-2 on
LTCCs.
The modulation of LTTCs in GT1-7 cells is very similar to
the voltage-independent inhibition of LTCCs induced by WIN
55,212-2 in NTS (nucleus tractus solitarius) neurons [22]. In these
neurons, activation of CB1R selectively inhibits the LTCCs in a
voltage-independent manner, with no effects on non-L-type chan-
nels (N-, P/Q- and R), while - and -opioid agonists selectively
inhibit the N- and P/Q-type currents in a voltage-dependent
manner. As for GT1-7 cells, the inhibition of LTCCs in NTS neu-
rons is reversible, cAMP/PKA-dependent and occurs within short
times (20–30 s), suggesting rather close coupling between CB1Rs,
Gi,o proteins, adenylate cyclases, cAMP/PKA and LTCCs. This is
somehow at variance with the slow up-regulatory effects of G
protein-coupled receptors mediated by the cAMP/PKA pathway on
LTCCs in myocytes [48], neuroendocrine cells [24,25,49,50], and
neuronal dendrites [51] (see [52] for a review). The most likely
explanation is that LTCCs modulation by cAMP/PKA is critically
controlled by the co-localization of G protein-coupled receptors,
Cav1.2 channels, adenylate cyclase and A-kinase anchoring pro-
teins (AKAPs) (reviewed by [53]) and thus its onset and offset could
vary greatly in different cell preparations. A possible difference
could derive from the type of LTCC involved. GT1-7 cells express
only Cav1.3 channels [31] whose modulation is not yet well stud-
ied.
Inhibition of LTCCs by WIN 55,212-2 has been reported also
in identified retinal bipolar cells [20] and in cerebral vascu-
lar smooth muscle cells [21]. In the latter case, WIN 55,212-2
and the endocannabinoid anandamide inhibited the LTCCs in a
voltage-independent manner and the effects were PTX-sensitive.
Despite these excellent agreements, however, other reports on the
effects of cannabinoids on LTCCs appear controversial. In NG108-
15 cells [9] and in lactotroph-derived GH4C1 cell line [17], LTCCs
are not affected by WIN 55,212-2 and cannabimimetic agonists
up-regulate Ca2+ influxes through LTCCs in N18TG2 cells via a PTX-
insensitive pathway [18].
4.2. Role of the CB1R-mediated inhibition of LTCCs in hormone
release and neuronal activity
LTCCs play a critical role in the control of electrical activity and
hormone release in GT1-7 neurons. Nimodipine is very effective in
changing the shape of action potential and reducing the frequency,
or even blocking, the spontaneous synchronized firing of GT1-7
neurons [28]. As the amount of intracellular Ca2+ inside a GT1-7
neuron is linearly related to the duration of spikes and depends
on the frequency of bursting, LTCCs activity appears extremely
critical in the control of GnRH release from GT1-7 cells. Several
reports indicate that the pulsatile release of GnRH from GT1-7 and
GT1-1 neuronal networks is largely controlled by LTCCs [28,29,54]
and only partially by R-type channels [31]. It is thus evident that
inhibition of LTCCs by cannabimimetic agonists is expected to pro-
duce marked reductions of cell firing activity, lower Ca2+ entry and
decreased release ofGnRH fromGT1-7neurons. This is indeedwhat
occurs when exogenous or endogenous cannabinoids are applied
to GT1-7 neurons. These cells express sufficient densities of CB1Rs
and possess the enzymes to produce and release endocannabi-
noids [27]. In this study,WIN55,212-2 (20–50M)was indeedvery
effective in reducing the KCl-stimulated release of GnRH in GT1-7
neurons. Both, PTX and the CB1R antagonist AM-281 blocked this
effect. As GnRH is the major regulator of reproduction in mammals
[55], these findings suggest that exogenous cannabinoids adminis-
tration may perturb reproduction through an inhibitory action on
hypothalamic GnRH neurons [27].
We found of great interest that cannabimimetic agonists selec-
tively inhibit the LTCCs controlling Ca2+-entry and GnRH release
in GT1-7 neurons and that CB1R activation reduces the pulsatile
release of GnRH from these cells [27]. The two effects are likely
to be linked and this broadens the number of signal transduction
pathways that might regulate the physiological and therapeutical
effects of cannabinoids. Ca2+ channel inhibition by endocannabi-
noids is functional in the control of GABA and glutamate release at
central synapses [15]. In addition, CB1Rs are among themost abun-
dant G protein-coupled receptors in the central nervous system
and are preferentially located at the synaptic terminals [3]. Since
endocannabinoids are synthesized and released postsynaptically
during periods of intense neuronal activity, the presynaptic local-
ization of CB1Rs suggests that these receptors might participate
in a form of feedback inhibition by reducing the activity of presy-
naptic Ca2+ channels (N- and P/Q-type). Following this scheme,
endocannabinoids are shown to be implicated in various forms of
synaptic plasticity [56].
Our findings add a new entry to the list of signal transduc-
tion pathways used by CB1R to control Ca2+ influx in neurons and
neuroendocrine cells that express LTCCs and CB1Rs. As LTCCs are
mainly expressed in the soma and proximal dendrites of neurons
and abundantly in neuroendocrine cells, their inhibition by CB1R
most likely will alter somatic activities and hormone release. For
instance, LTCCs activating at subthreshold potentials are expressed
in midbrain dopaminergic neurons of substantia nigra [57] and
hypothalamic suprachiasmatic nucleus neurons [58], which also
express high densities of CB1R [59]. LTCCs regulate the shape of
action potentials and the frequency of spontaneous firing [60], thus
an effective up- or down-modulation of these channels by CB1R
activation or deactivation can cause drastic changes to neuronal
firing, neurotransmitter release and brain functions control.
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5. Conclusions
Our results suggest that the selective effects of CB1R agonists
and inverse agonists on neuronal LTCCs may broaden our current
understanding of the cannabinoids use in the treatment of several
neurological diseases [61].Neuronsexpressdifferent typesof LTCCs
(Cav1.2, Cav1.3 and Cav1.4) which regulate membrane excitability,
action potential firing, intracellular signal transduction pathways,
synaptic plasticity and synapse formation. Thus, it would not be
surprising that some of the therapeutic effects of cannabinoids
on central and peripheral neurons, such as analgesia, sedation,
improvement of mood, stimulation of appetite, anti-emesis and
neuroprotection, may derive directly or indirectly from the CB1R-
induced inhibition or potentiation of LTCCs.
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